Skip to main
COYA

COYA Stock Forecast & Price Target

COYA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coya Therapeutics is a promising player in the biotech industry, with a focus on developing innovative therapies for chronic diseases with high unmet medical needs. Despite the risks associated with regulatory and clinical success, the company's current pipeline, including the COYA-302 combination strategy and the FTD and ALS treatment programs, has the potential for substantial growth and market exclusivity. However, the company will need to secure additional funding in the future, which may be challenging in the competitive biotech market.

Bears say

Coya Therapeutics is a clinical-stage biotechnology company that may face potential financing risks and is heavily reliant on the success of its lead product candidate, COYA 302. Additionally, the market for SMid-Cap stocks has been volatile without company-specific fundamental reasons, which may result in substantial losses for investors. Furthermore, the company faces significant competition from other major pharmaceutical companies and specialized biotechnology firms. These factors, along with the need for future fundraising and potential regulatory hurdles, contribute to the negative outlook on Coya Therapeutics' stock.

COYA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coya Therapeutics Inc (COYA) Forecast

Analysts have given COYA a Strong Buy based on their latest research and market trends.

According to 5 analysts, COYA has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coya Therapeutics Inc (COYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.